<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1471" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="832" end="837"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="1024" end="1034"/>
    <type:OSMean xmi:id="21" sofa="6" begin="1071" end="1081"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Three-drug combination of fluoropyrimidine, irinotecan and oxaliplatin has shown &#13;&#10;survival benefits in patients with metastatic colorectal cancer (mCRC). Recently &#13;&#10;we performed a phase II study of a new 3-drug regimen, TIROX (S-1 plus irinotecan&#13;&#10;and oxaliplatin) to evaluate efficacy and safety in refractory mCRC patients.&#13;&#10;Patients with refractory to all of 3 drugs, age &gt; or = 18 years, PS 0-2, &gt; or = 1&#13;&#10;measurable lesion(s) and adequate organ functions were eligible. S-1 was given 40&#13;&#10;mg/m(2) twice a day on D1-14, oxaliplatin 85 mg/m(2) and irinotecan 150 mg/m(2)&#13;&#10;on D1 every 3 weeks. The primary endpoint was overall response rate (ORR).&#13;&#10;Between Mar 2007 and Nov 2007, 19 patients (of 18 planned) were enrolled; median &#13;&#10;age 50 years; M/F 12/7; PS 0/1/2 5/13/1; colon/rectum 11/8. By intent-to-treat&#13;&#10;analysis, ORR was 21.1% (95% CI, 8.7-43.7) and disease control rate was 52.6%&#13;&#10;(95% CI 31.5-72.8) with four PRs and six SDs. Median duration of disease control &#13;&#10;was 4.3 months (95% CI 1.7-6.9). Median PFS was 2.6 months (95% CI 2.2-2.9) and&#13;&#10;median OS was 9.8 months (95% CI 5.3-14.4) after median F/U of 15.4 months. G3/4 &#13;&#10;toxicities per pt included neutropenia (five, 26.3%), febrile neutropenia (two,&#13;&#10;10.5%), thrombocytopenia (one, 5.3%), diarrhea (two, 10.5%) and fatigue (two,&#13;&#10;10.5%). TIROX seemed to be feasible and efficacious for refractory mCRC patients,&#13;&#10;and could be an alternative for patients with good PS but no further treatment&#13;&#10;options."/>
    <cas:View sofa="6" members="1 13 17 21"/>
</xmi:XMI>
